Lenvatinib

Lenvatinib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC₅₀s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC₅₀s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

Verwenden

E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.

Definition

ChEBI: A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.

Nebenwirkungen

The most common side effects of LENVIMA (lenvatinib) in people treated for thyroid cancer include tiredness; joint and muscle pain; decreased appetite; weight loss; nausea; mouth sores; headache; vomiting; rash, redness, itching, or peeling of your skin on your hands and feet; stomach (abdomen) pain; and hoarseness.
The most common side effects of LENVIMA when given with everolimus in people treated for kidney cancer include tiredness; joint and muscle pain; decreased appetite; vomiting; nausea; mouth sores; swelling in your arms and legs; cough; stomach (abdomen) pain; trouble breathing; rash; weight loss; and bleeding.
The most common side effects of LENVIMA in people treated for liver cancer include tiredness; decreased appetite; joint and muscle pain; weight loss; stomach (abdomen) pain; rash, redness, itching, or peeling of your skin on your hands and feet; hoarseness; bleeding; change in thyroid hormone levels; nausea.

Lenvatinib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Lenvatinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Baoji Guokang Healthchem co.,ltd	+8615604608665 15604608665	dominicguo@gk-bio.com	CHINA	9427	58
Senova Technology Co. Ltd.	+86-0755-86703119 +8618503098836	info@senovatech.com	China	350	58
Zhengzhou Anhuida Chemical Co., Ltd	+8615903659408	admin@ahdchem.com	China	298	58
Hebei Guanlang Biotechnology Co,.LTD	+8619930503252	daisy@crovellbio.com	China	5961	58
Hebei Dangtong Import and export Co LTD	+8615632927689	admin@hbdangtong.com	China	985	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2503	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	11013	58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-0531-69954981 +8615666777973	dwyane.wang@boyuanpharm.com	China	211	58
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55

417716-92-8()Verwandte Suche:

---

• 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
• E7080 (Lenvatinib)
• ER-203492-00
• 1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea
• 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445
• E70801-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea
• 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate
• LENVATINIB
• E7080; VARGATEF; E-7080; E 7080
• CS-384
• Lenvatinib base,Lenvatinib
• envatinib (E7080)
• Lenvatinib base
• Levatinib Impurity 13
• E7081）
• Lenvatini
• 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-
• Lenvatinib (free base)
• Lenvatinib USP/EP/BP
• Lenvatinib Impurity 134
• Lenvatinib Impurity 127
• Lenvatinib Impurity 128
• Lenvatinib Impurity 129
• Lenvatinib Impurity 130
• Lenvatinib Impurity 131
• Lenvatinib Impurity 132
• Lenvatinib Impurity 133
• E7080
• Lenvatinib (E7080)
• 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
• 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
• Lenvima
• Lenvatinib-d4
• methyl 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxylate
• 1,10-Phenanthroline-5,6-dione,2,13-dimethyl-
• Benzaldehyde,2,4-dibromo-9-hydroxy-
• Lovartinib free base
• 4-{3-Chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-N-cyclopropyl-7-methoxyquinoline-6-carboxamide
• Top quality 417716-92-8 Lenvatinib
• Lombartinib impurity
• Levantinib
• Lenavatinib Mesylate
• 417716-92-8
• 17716-92-8
• 417716-92-9
• Inhibitors
• FGF receptor antagonist
• API
• 417716-92-8
• Intermediate